|Year : 2019 | Volume
| Issue : 2 | Page : 75-82
Review of oral anticholinergics in the treatment of palmoplantar hyperhidrosis
Swetalina Pradhan1, Bhushan Madke2, Chandra Sekhar Sirka3
1 Department of Dermatology and Venereology, All India Institute of Medical Sciences, Patna, Bihar, India
2 Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College and AVBR Hospital, Wardha, Maharashtra, India
3 Department of Dermatology and Venereology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
|Date of Web Publication||16-Dec-2019|
Dr. Bhushan Madke
Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College and AVBR Hospital, Sawangi, Wardha - 442 001, Maharashtra
Source of Support: None, Conflict of Interest: None
Hyperhidrosis (HH) is the excessive production of sweating, which can be primary and focal or secondary. The most commonly affected sites are the armpits, palms, soles, and face. It causes much discomfort and affects self-esteem and quality of life. Many treatment options have been proposed, both medical and surgical. Several recent studies have documented the effectiveness of oral anticholinergics in both focal and generalized HH regardless of age, gender, and weight. This article is an attempt to update the current status of oral anticholinergics in the treatment of palmoplantar HH.
Keywords: Hyperhidrosis, oral anticholinergics, review
|How to cite this article:|
Pradhan S, Madke B, Sirka CS. Review of oral anticholinergics in the treatment of palmoplantar hyperhidrosis. Indian J Drugs Dermatol 2019;5:75-82
|How to cite this URL:|
Pradhan S, Madke B, Sirka CS. Review of oral anticholinergics in the treatment of palmoplantar hyperhidrosis. Indian J Drugs Dermatol [serial online] 2019 [cited 2020 Feb 17];5:75-82. Available from: http://www.ijdd.in/text.asp?2019/5/2/75/272960
| Introduction|| |
Hyperhidrosis (HH) is a disorder characterized by the increased production of sweat disproportionate to the amount required to compensate for environmental conditions or thermoregulatory needs. Studies from several parts of the world have been addressing the epidemiology of HH, but in most of them, a limited portion of populations has been analyzed, thus their conclusions cannot be generalized.
HH can be primary or secondary in nature and may have general, regional, or focal manifestations. Primary HH is most often focal and generally causes idiopathic, symmetrically bilateral excessive sweating of the axillae, palms, soles, or craniofacial region. Secondary HH manifests most often as generalized excessive sweating that is related to an underlying medical condition or use of medications. HH results in a decrease in quality of life, may cause impairment in the ability to carry out daily functions, and, in some cases, may increase the risk of cutaneous infections.,
Magnitude of problem
There have been contradictory reports from various studies conducted in various countries such as Japan, Germany, Poland, and Canada regarding gender distribution in HH.,,, However, in majority of the studies, men have been found to have higher incidence and intensity of HH compared to women.,,, Men are more likely to have craniofacial HH or “additional areas” involved, whereas women are more likely to have axillary HH.
| Management of Hyperhidrosis|| |
Therapeutic options for HH are divided into several categories including topical, oral, and injectable drugs and medical devices.
Antiperspirant preparations containing aluminum salts, glycopyrrolate 2%, formaldehyde, and glutaraldehyde salts are the commonly used topical preparations for HH. Aluminum salts are the first-line treatment for HH because of their safety profile, cost-effectiveness, and efficacy.,, Antiperspirants work by obstructing the distal eccrine sweat gland ducts and long-term blockage, leading to functional and structural degeneration of the eccrine acini and thereby reducing sweat production., Skin irritation is a common limiting adverse event with aluminum chloride hexahydrate.,
Topical glycopyrrolate 2% improves HH because of its anticholinergic action by competitively binding the muscarinic acetylcholine receptors (Ach R). Studies and case reports suggest good results in facial HH, whereas results on axillary HH were inconsistent.,, Formaldehyde and glutaraldehyde are not commonly used in the treatment of primary focal HH because of their side effects such as localized skin irritation, allergic sensitization, and central nervous system toxicity.,
Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent. Various types of botulinum toxins have been tried in axillary and palmoplantar HH.,,,,,,,,,, The administration of botulinum toxin requires multiple injections, and expertise to inject proper amount of the toxin at proper site and the procedure is painful. Apart from discomfort, it is costly and unaffordable by patients in resourcepoor settings.,, Therapeutic failure owing to antibody formation is possible but extremely rare.
Tap water iontophoresis (TPI) has been used as a mode of treatment for HH where an ionized substance is used for passing through the intact skin with the help of a device that delivers 15–20 mA of current through tap water.,
According to proposed hypotheses, it acts through the inhibition of sympathetic nerve transmission, ion deposition obstructing the sweat gland, and local alterations of pH inhibiting the sweat gland.,,, Although TPI is found to be effective, it requires multiple sessions and maintenance therapy and is very time-consuming. In addition, it can cause discomfort, vesiculation, and erythema.
Apart from TPI, various emerging modalities, for example, microwave technology, lasers, microneedle radiofrequency, and ultrasound, are recently used for a focused area of thermotherapy targeting the eccrine sweat glands. However, they are cumbersome and costly and require multiple sessions and expertise.,,,,,
Sympathectomy is used especially in palmar HH. Wolosker et al. evaluated quality of life in 453 patients prospectively for 5 years following endoscopic thoracic sympathectomy and found that 409 patients (90.3%) had improved quality of life and only 3.1% of the patients had worsening results. In a study, more than 90% of patients had improved quality of life following sympathectomy and severe compensatory HH occurred in 5.4% of patients. Age did not affect these outcomes. Although long-term improvement has been found in 79% of cases, the procedure has the drawback of development of compensatory HH in body areas that are not supplied by the upper nerve trunk. In addition, there is a risk of surgery-related complications such as hemothorax, pneumothorax, Horner's syndrome, injury to the thoracic duct, and damage to the phrenic nerve.
For axillary HH, removal of axillary sweat glands by complete axillary curettage or liposuction has been tried, with success rate being 90%., However, the procedure needs skilled expertise and carries a risk of postprocedural complications of wound infection, scar formation, skin necrosis, and skin discoloration.
All the above-mentioned therapeutic approaches show a specific safety and effective profile to control primary HH localized at the axilla, the palms of the hands, the soles of the feet, and the face, and some of them have also demonstrated efficacy in segmental compensatory HH. Generalized HH requires systemic treatment and other modalities can be used as an adjuvant. Oral anticholinergics, beta-blockers, benzodiazepines, methanthelinium bromide, and clonidine have been used for the treatment of HH and among them, oral anticholinergics are commonly used for HH. In this review, we will discuss various types of oral anticholinergics in the management of HH.
| Oral Anticholinergics|| |
HH is believed to be caused by overactive cholinergic input to the eccrine glands.
Overexpression of acetylcholine and α 7-nicotinic receptors in sympathetic ganglia has been demonstrated in HH patients. Among oral anticholinergics, oxybutynin and glycopyrrolate have been studied widely for the management of HH.
Over the years, several studies have demonstrated good results of oxybutynin in focal HH (axillary, facial, and palmoplantar) and generalized HH.,,,,
Mechanism of action
Oxybutynin is an oral anticholinergic medication having antagonistic action on M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor (Ach R). Its antimuscarinic effect on HH was first reported in 1988.,
Oxybutynin is rapidly absorbed, achieving the maximum concentration within an hour of oral intake after which plasma concentration decreases. The effective half-life of the drug is approximately 2–3 h. The absolute bioavailability of oxybutynin is reported to be about 6% (range, 1.6–10.9). Food delays the absorption and thereby increases the bioavailability of oxybutynin by 25%.
Oxybutynin is widely distributed in body tissues following systemic absorption. The major binding protein is α-1 acid glycoprotein.,, The drug can cross blood–brain barrier.
Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. The metabolism results in one pharmacologically active product des-ethyl oxybutynin and a pharmacologically inactive product phenylcyclohexylglycolic acid.,,
Oxybutynin is extensively metabolized by the liver, with <0.1% of the administered dose excreted unchanged in the urine and <0.1% of the administered dose excreted as the metabolite des-ethyl oxybutynin.,,
Oxybutynin is a pregnancy category B drug. Oxybutynin chloride should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.,,
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce side effects similar to anticholinergics should be avoided.,, Due to anticholinergic effect on gastrointestinal (GI) motility, oxybutynin may alter the absorption of some concomitantly administered drugs. Ketoconazole being a potent CYP3A4 inhibitor increases the mean oxybutynin chloride plasma concentrations three- to four-fold. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the oxybutynin's mean pharmacokinetic parameters (i.e., maximum concentration and area under the curve).,,
Different studies have followed the following regimen – oral oxybutynin 2.5 mg daily for the 1st week, then 2.5 mg twice daily from day 8 to day 21, and 5 mg twice daily starting at day 22 up to 6 months for HH.,, The drug can be taken with or without food.
- Absolute contraindication: Angle-closure glaucoma
- Relative contraindication: Urinary retention, severe bladder outflow obstruction, gastric retention, GI obstruction, severe toxic megacolon, and hypersensitivity to the drug substance or other components of the product.
Side effect profile
Side effects are mainly due to the antimuscarinic effects of the drug. Dry mouth is experienced by 70%–100% of the patients treated with oxybutynin for HH. Other adverse events observed include constipation in up to 31% of the patients and drowsiness in up to 18%, while a feeling of mild urinary retention, dry eyes, dizziness, blurred vision, diarrhea, mydriasis, dry skin, rash, photosensitivity, and flushing are seen rarely.
The anticholinergic effects are more frequent with doses over 15 mg/day. A maximum dose of 10 mg/day reached through slow and progressive increase in dosage over a period of 3 weeks lowers the incidence of side effects, maintaining effectiveness and improving compliance to treatment. Schedules of a 1.25-mg initial dose and an increase by 1.25 mg every 4 days up to 7.5 mg/day, or 2.5 mg/day for the 1st week, 2.5 mg twice a day for the next 2 weeks, and 5 mg twice daily for the rest of the treatment have been successfully employed in literature.
Glycopyrrolate (pyrrolidinium 3-[(cyclopentylhydroxy/phenylacetyl) oxyl]-1, l-dimethyl bromide; glycopyrronium bromide) is a quaternary ammonium anticholinergic drug.
Mechanism of action
It competitively inhibits the action of acetylcholine at muscarinic receptors, which are prominent in glandular tissue. It also induces smooth muscle relaxation. It is a known antisecretory drug, thereby reducing gastric, pharyngeal, tracheal, and bronchial secretions.
Following oral administration, absorption from the GI tract is poor. Only 10%–25% of the drug is absorbed after oral intake. There is poor penetration of the drug across the blood–brain barrier. Both animal and human studies showed that placental transfer is limited.,
Metabolism and excretion
The major metabolic pathway is hydroxylation of the cyclopentyl ring and oxidation of the hydroxyl group in the mandelic acid residue which occurs in liver. The drug is chiefly excreted through urine and bile.
In various studies, the effective mean dose of glycopyrrolate in adult patients with primary HH was 2 mg once to twice daily., The efficacy is higher in children than in adults in controlling HH (90% efficacy with a mean dosage of 2 mg daily), and significant side effects in children are unusual.
The drug may antagonize the GI effects of prokinetic drugs (metoclopramide and domperidone).
Pregnancy category: Category B
Side effects of glycopyrrolate include xerostomia, loss of taste, nausea, vomiting, constipation, erectile dysfunction, headache, urinary retention and hesitancy, tachycardia, feeling of bloating, ocular effects (dry eyes and cycloplegia), and dizziness. Potentially fatal result can occur due to severe anaphylaxis.
The drug should be used with caution in those with close-angle glaucoma, bladder outflow obstruction, gastro-esophageal reflux disease, and cardiac insufficiency. It is contraindicated in those with myasthenia gravis, paralytic ileus, and pyloric stenosis.
Current literature on the efficacy of oral anticholinergic drugs are summarized in [Table 1] and [Table 2].
| Conclusion|| |
Oral anticholinergic drugs are safe therapeutic options in the treatment of focal HH, especially in resource-poor settings. Oxybutynin and glycopyrrolate are currently available in the Indian market. The drugs need close monitoring for their side effect profile. The authors suggest a tailor-made dosing schedule in real clinical settings.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al.
A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007;33:908-23.
Estevan FA, Wolosker MB, Wolosker N, Puech-Leão P. Epidemiologic analysis of prevalence of the hyperhidrosis. An Bras Dermatol 2017;92:630-4.
Lowe N, Campanati A, Bodokh I, Cliff S, Jaen P, Kreyden O, et al.
The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 2004;151:1115-22.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: A case-control study of 387 patients. J Am Acad Dermatol 2009;61:242-6.
Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K, et al.
Focal hyperhidrosis: Effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301-4.
Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: From questionnaire analysis. J Dermatol 2013;40:886-90.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I, et al.
Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 2013;227:10-3.
Stefaniak T, Tomaszewski KA, Proczko-Markuszewska M, Idestal A, Royton A, Abi-Khalil C, et al.
Is subjective hyperhidrosis assessment sufficient enough? Prevalence of hyperhidrosis among young Polish adults. J Dermatol 2013;40:819-23.
Lear W, Kessler E, Solish N, Glaser DA. An epidemiological study of hyperhidrosis. Dermatol Surg 2007;33:S69-75.
Moraites E, Vaughn OA, Hill S. Incidence and prevalence of hyperhidrosis. Dermatol Clin 2014;32:457-65.
Shelley WB, Hurley HJ Jr. Studies on topical antiperspirant control of axillary hyperhidrosis. Acta Derm Venereol 1975;55:241-60.
Brandrup F, Larsen PO. Axillary hyperhidrosis: Local treatment with aluminum chloride hexahydrate 25% in absolute ethanol. Acta Derm Venereol 1978;58:461-5.
Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol 1990;29:368-70.
Hölzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol 1984;110:399-403.
Hölzle E. Topical pharmacological treatment. Curr Probl Dermatol 2002;30:30-43.
White JW Jr. Treatment of primary hyperhidrosis. Mayo Clin Proc 1986;61:951-6.
Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007;157:118-21.
Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008;158:1094-7.
Hyun MY, Son IP, Lee Y, Choi HG, Park KY, Li K, et al.
Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: A randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol 2015;29:278-82.
Mackenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol 2013;169:483-4.
Songur A, Ozen OA, Sarsilmaz M. The toxic effects of formaldehyde on the nervous system. Rev Environ Contam Toxicol 2010;203:105-18.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: Randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596-9.
Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 2002;28:480-3.
Naumann M, Lowe NJ, Kumar CR, Hamm H; Hyperhidrosis Clinical Investigators Group. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: A prospective study. Arch Dermatol 2003;139:731-6.
Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: A study of 28 patients. J Am Acad Dermatol 2014;70:1083-7.
Rystedt A, Swartling C, Färnstrand C, Naver H. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol 2008;88:458-61.
Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: Randomized, single-blind, two-dose study. Neurology 2001;57:2095-9.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:1041-5.
Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997;136:548-52.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: A double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28:822-7.
D'Epiro S, Macaluso L, Salvi M, Luci C, Mattozzi C, Marzocca F, et al.
Safety and prolonged efficacy of botulin toxin A in primary hyperhidrosis. Clin Ter 2014;165:e395-400.
Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin 2014;32:505-15.
Kuwahara RT, Skinner RB. Emla versus ice as a topical anesthetic. Dermatol Surg 2001;27:495-6.
Dixit S, Lowe P, Fischer G, Lim A. Ice anaesthesia in procedural dermatology. Australas J Dermatol 2013;54:273-6.
Patel R, Halem M, Zaiac M. The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. J Drugs Dermatol 2009;8:948-51.
Wörle B, Rapprich S, Heckmann M. Definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges 2007;5:625-8.
Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Dermatol 1968;98:505-7.
Nagar R, Sengar SS. A simple user-made iontophoresis device for palmoplantar hyperhidrosis. J Cutan Aesthet Surg 2016;9:32-3.
] [Full text]
Thomas L, Fatah S, Carmichael AJ. Tap water iontophoresis may be ineffective for axillary hyperhidrosis. Clin Exp Dermatol 2015;40:337-8.
Hill AC, Baker GF, Jansen GT. Mechanism of action of iontophoresis in the treatment of palmar hyperhidrosis. Cutis 1981;28:69-70, 72.
Wang L, Hilliges M, Gajecki M, Marcusson JA, Johansson O. No change in skin innervation in patients with palmar hyperhidrosis treated with tap-water iontophoresis. Br J Dermatol 1994;131:742-3.
Anliker MD, Kreyden OP. Tap water iontophoresis. Curr Probl Dermatol 2002;30:48-56.
Karakoç Y, Aydemir EH, Kalkan MT, Unal G. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol 2002;41:602-5.
Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 1987;123:893-6.
Schick CH, Grallath T, Schick KS, Hashmonai M. Radiofrequency thermotherapy for treating axillary hyperhidrosis. Dermatol Surg 2016;42:624-30.
Kim M, Shin JY, Lee J, Kim JY, Oh SH. Efficacy of fractional microneedle radiofrequency device in the treatment of primary axillary hyperhidrosis: A pilot study. Dermatology 2013;227:243-9.
Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: A sham control study. Australas J Dermatol 2015;56:279-84.
Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd: YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 2012;11:59-63.
Bechara FG, Georgas D, Sand M, Stücker M, Othlinghaus N, Altmeyer P, et al.
Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: A randomized controlled half-side comparison study. Dermatol Surg 2012;38:736-40.
Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol 2014;7:14-21.
Claes G. Indications for endoscopic thoracic sympathectomy. Clin Auton Res 2003;13 Suppl 1:I16-9.
Wolosker N, de Campos JR, Kauffman P, de Oliveira LA, Munia MA, Jatene FB. Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. J Vasc Surg 2012;55:154-6.
Leiderman DB, Milanez de Campos JR, Kauffman P, Tedde ML, Yazbek G, Teivelis MP, et al.
The relation between age and outcomes of thoracic sympathectomy for hyperhidrosis: The older the better. J Thorac Cardiovasc Surg 2018;156:1748-56.
Lin TS, Fang HY. Transthoracic endoscopic sympathectomy in the treatment of palmar hyperhidrosis – with emphasis on perioperative management (1,360 case analyses). Surg Neurol 1999;52:453-7.
Wollina U, Köstler E, Schönlebe J, Haroske G. Tumescent suction curettage versus minimal skin resection with subcutaneous curettage of sweat glands in axillary hyperhidrosis. Dermatol Surg 2008;34:709-16.
Lillis PJ, Coleman WP, 3rd
. Liposuction for treatment of axillary hyperhidrosis. Dermatol Clin 1990;8:479-82.
Solish N, Benohanian A, Kowalski JW; Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: Effects on functional impairment and quality of life. Dermatol Surg 2005;31:405-13.
de Moura Júnior NB, das-Neves-Pereira JC, de Oliveira FR, Jatene FB, Parra ER, Capelozzi VL, et al.
Expression of acetylcholine and its receptor in human sympathetic ganglia in primary hyperhidrosis. Ann Thorac Surg 2013;95:465-70.
Wolosker N, de Campos JR, Kauffman P, Neves S, Munia MA, BiscegliJatene F, et al.
The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg 2011;25:1057-62.
Wolosker N, Campos JR, Kauffman P, Munia MA, Neves S, Jatene FB, et al.
The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 2011;86:451-6.
Wolosker N, de Campos JR, Kauffman P, Neves S, Yazbek G, Jatene FB, et al.
An alternative to treat palmar hyperhidrosis: Use of oxybutynin. Clin Auton Res 2011;21:389-93.
Wolosker N, de Campos JR, Kauffman P, Yazbek G, Neves S, Puech-Leao P. Use of oxybutynin for treating plantar hyperhidrosis. Int J Dermatol 2013;52:620-3.
Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012;55:1696-700.
Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47-50.
LeWitt P. Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 1988;38:506-7.
Yong C, Yu D, Eden L, Eichmeyer L, Giessing D. Effect of food on the pharmacokinetics of oxybutynin in normal subjects. Pharm Res 1991;8:S320.
Hughes KM, Lang JC, Lazare R, Gordon D, Stanton SL, Malone-Lee J, et al.
Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69.
Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62.
Wolosker N, Teivelis MP, Krutman M, de Paula RP, Kauffman P, de Campos JR, et al.
Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis. Ann Vasc Surg 2014;28:1106-12.
Wolosker N, Teivelis MP, Krutman M, de Paula RP, de Campos JR, Kauffman P, et al.
Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res 2014;24:297-303.
Costa Ada S Jr., Leão LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, et al.
Randomized trial – Oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. Clinics (Sao Paulo) 2014;69:101-5.
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al.
Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65.
Try C, Messikh R, Elkhyat A, Aubin F, Humbert RP. Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis. Rev Med Liege 2012;67:520-6.
Matsui M, Yamada S, Oki T, Manabe T, Taketo MM, Ehlert FJ. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci 2004;75:2971-81.
Proakis AG, Harris GB. Comparative penetration of glycopyrrolate and atropine across the blood – Brain and placental barriers in anesthetized dogs. Anesthesiology 1978;48:339-44.
Abboud TK, Read J, Miller F, Chen T, Valle R, Henriksen EH. Use of glycopyrrolate in the parturient: Effect on the maternal and fetal heart and uterine activity. Obstet Gynecol 1981;57:224-7.
Mirakhur RK, Dundee JW. Glycopyrrolate: Pharmacology and clinical use. Anaesthesia 1983;38:1195-204.
Walling HW. Systemic therapy for primary hyperhidrosis: A retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 2012;66:387-92.
Paller AS, Shah PR, Silverio AM, Wagner A, Chamlin SL, Mancini AJ. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 2012;67:918-23.
Kim WO, Kil HK, Yoon KB, Yoo JH. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. Acta Derm Venereol 2010;90:291-3.
Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, Zagnoli A, Chassain-Le Lay M, et al.
Oxybutynin as a treatment for generalized hyperhidrosis: A randomized, placebo-controlled trial. Br J Dermatol 2015;173:1163-8.
Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 2006;142:1065-6.
Wolosker N, Krutman M, Kauffman P, Paula RP, Campos JR, Puech-Leão P, et al.
Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients. Rev Assoc Med Bras (1992) 2013;59:143-7.
Wolosker N, Krutman M, Teivelis MP, Paula RP, Kauffman P, Campos JR, et al.
Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years. Einstein (Sao Paulo) 2014;12:42-7.
Wolosker N, Krutman M, Campdell TP, Kauffman P, Campos JR, Puech-Leão P, et al.
Oxybutynin treatment for hyperhidrosis: A comparative analysis between genders. Einstein (Sao Paulo) 2012;10:405-8.
Wolosker N, Krutman M, Teivelis MP, Campbell TP, Kauffman P, de Campos JR, et al.
Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. Ann Vasc Surg 2014;28:970-6.
Wolosker N, Teivelis MP, Krutman M, de Paula RP, Schvartsman C, Kauffman P, et al.
Long-term efficacy of oxybutynin for palmar and plantar hyperhidrosis in children younger than 14 years. Pediatr Dermatol 2015;32:663-7.
Lee HH, Kim DW, Kim DW, Kim C. Efficacy of glycopyrrolate in primary hyperhidrosis patients. Korean J Pain 2012;25:28-32.
Gong TK, Kim DW. Effectiveness of oral glycopyrrolate use in compensatory hyperhidrosis patients. Korean J Pain 2013;26:89-93.
Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyrrolate for refractory pediatric and adolescent hyperhidrosis. Pediatr Dermatol 2014;31:e28-30.
[Table 1], [Table 2]